BioAdaptives, Inc. (BDPT) stock
Close on Oct 19, 2026Market cap $478.03KP/E –Yield –
BioAdaptives, Inc. grew revenue 694.1% to $25.56K over the twelve months to Jun 30, 2026. Free cash flow was -$534.03K. At the latest close the market valued the company at $478.03K.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $478.03K
- P/E ratio
- –
- Price to sales
- 18.70
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -111.71%
Fundamentals
- Revenue
- $25.56K
- Net income
- -$1.16M
- EPS, diluted
- -$0.12
- Free cash flow
- -$534.03K
- Book value per share
- -$0.01
- Diluted shares
- 281M
Trading
- Previous close
- $0.00
- Open
- $0.00
- Day's range
- $0.00 – $0.00
- Volume
- 20,884,764
- Average volume (20 days)
- 23,105,695
Market cap history
Month-end market cap since 2014, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | BDPT | S&P 500 | Difference | BDPT per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | 0.0% | +0.6% | −0.6 pts | ||
| 3 months | +6.3% | +3.4% | +2.9 pts | ||
| Year to date | -92.3% | +13.3% | −105.6 pts | ||
| 1 year | -93.7% | +16.6% | −110.3 pts | ||
| 3 years | -99.1% | +86.4% | −185.5 pts | -79.4% | +23.1% |
| 5 years | -100.0% | +81.9% | −181.8 pts | -78.7% | +12.7% |
| 10 years | -100.0% | +318.9% | −418.8 pts | -62.7% | +15.4% |
Twelve years at a glance
Fiscal years 2013 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases BioAdaptives filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Update
- Update
- Update
- Update
About BioAdaptives
Pharmaceutical Preparations
BioAdaptives, Inc. researches, develops, markets, and distributes natural nutraceutical products and medical devices designed to support human and animal health. Its portfolio features plant-, fungal-, and algal-based dietary supplements targeting cognitive enhancement, regenerative wellness, and weight management, with brand offerings including MyndMed, Xcellara, Zeranovia, Wynovia, and PawPa Regen canine chews. The company also distributes the Lung Flute, an FDA-cleared respiratory medical device. BioAdaptives serves consumers directly through digital marketing channels and reaches patients via partnerships with telehealth platforms, medical communities, pharmacies, athletic clubs, and senior living communities.
Company profile, executives and historyBioAdaptives stock: common questions
What is BioAdaptives's stock price?
BDPT closed at $0.00 on Oct 19, 2026, down 5.56% on the day.
What is BioAdaptives's market cap?
BioAdaptives was worth $478.03K at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
What is BDPT's P/E ratio?
BioAdaptives lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.12), so it has no meaningful P/E ratio.
How much revenue does BioAdaptives make?
BioAdaptives reported revenue of $25.56K for the twelve months to Jun 30, 2026, up 694.1% from a year earlier.
Does BioAdaptives pay a dividend?
No. BioAdaptives has not paid a cash dividend over the last twelve months.
How has BDPT stock performed over the past year?
Including dividends, BDPT returned -93.7% over the past year, against +16.6% for the S&P 500.
Who are BioAdaptives's competitors?
Companies most similar to BioAdaptives by business, industry and size include JUNS, SKVI, ADXN, SILO, PRFX.
See a number that looks wrong?